NewsBenzingaUBS mantiene su recomendación de compra sobre Syndax Pharmaceuticals y reduce el precio objetivo a 31 dólares UBS mantiene su recomendación de compra sobre Syndax Pharmaceuticals y reduce el precio objetivo a 31 dólares Benzinga 2026.11.20 18:27 (GMT+0) Open on Benzinga Other news KGI Securities Downgrades Lowe's Companies to Neutral, Announces $231 Price Target ETH Falls Below $1,600, Down 3.35% Intraday Johnson Rice Upgrades Crescent Energy to Buy, Announces $20 Price Target Johnson Rice Upgrades Viper Energy to Buy, Announces $58 Price Target 'GTA 6' Money Saver? Entrepreneur Says $100 Game Could Save You $5,000 Johnson Rice Downgrades Mach Natural Resources to Accumulate, Announces $13 Price Target